{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:35Z","timestamp":1792036835520,"version":"4.4.0"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA222518"],"award-info":[{"award-number":["R01CA222518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA253981"],"award-info":[{"award-number":["R01CA253981"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266604"],"award-info":[{"award-number":["R01CA266604"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01DK124788"],"award-info":[{"award-number":["R01DK124788"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Edwards P. Evans Foundation"},{"name":"Frederick DeLuca Foundation"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>RNA splicing factor (SF) mutations are associated with adverse outcomes in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes\/neoplasms (HR-MDS). Preclinical data suggest that aberrant RNA splicing can lead to the generation of neoantigens, which renders these tumors more susceptible to immune checkpoint inhibitors. However, dedicated studies on immune checkpoint inhibitors in AML and MDS patients with SF mutations are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To characterize the immune and epigenetic landscape of AML and MDS patients with SF mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>\n                      Post hoc analysis of the impact of RNA SF mutations (defined as any of\n                      <jats:italic toggle=\"yes\">SF3B1, SRSF2, U2AF1<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">ZRSR2<\/jats:italic>\n                      ) on outcomes of newly diagnosed, older or intensive chemotherapy-ineligible patients with AML or HR-MDS treated with azacitidine \u00b1 the anti-PD-L1 antibody durvalumab as part of the randomized, phase II FUSION trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Primary endpoint was the overall response rate (ORR). Flow cytometry and gene expression profiling using bulk RNA sequencing were performed on pretreatment bone marrow aspirate samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred twenty-six patients with AML (51 SF-mutant and 75 wild type) and 79 patients with MDS (33 SF-mutant and 46 wild type) were included. ORR was independent of SF mutation status for both AML (SF-mutant: 35.3% vs wild-type: 33.3%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.47) and MDS patients (51.5% vs 56.5%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.63). Median overall survival was similar for SF-mutant and wild-type AML (14.9 months vs 12.2 months;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.50) and MDS patients (23.5 months vs 10.6 months;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.16). There were no differences in key cell populations from bone marrow aspirate flow cytometry samples. Gene expression analyses showed an increase in MKI-67 expression in SF wild-type patients, but no differences were observed in several immune-related genes including IL7R and PD-L1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Addition of durvalumab to azacitidine did not improve ORR or OS among older patients with newly diagnosed AML and HR-MDS independent of SF mutation status.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration:<\/jats:bold>\n                      NCT02775903\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251347344","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T09:48:26Z","timestamp":1750499306000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine \u00b1 Durvalumab"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Hasle","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Thompson","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lopes de Menezes","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelonitda","family":"Rose","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Boss","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Kewan","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Fox","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00384-z"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004260"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26757"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004850"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01328-9"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02050-4"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.038"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006138"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241257904"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.800267"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02175-0"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020649"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01437-1"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.12.002"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.815037"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251347344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251347344","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251347344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:48Z","timestamp":1777591068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251347344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":18,"alternative-id":["10.1177\/20406207251347344"],"URL":"https:\/\/doi.org\/10.1177\/20406207251347344","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"article-number":"20406207251347344"}}